Although the specific reasons for these differences were unclear, biomolecular studies suggested that the more favorable prognosis of patients with 19 Del lung cancer was due to better responses to EGFR - TKI by 19 Del lung cancer than by L858R lung cancer [27, 28]. This evidence concerns the gene EGFR and lung cancer.